Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00063687 · ClinicalTrials.gov registry record · Phase 2
Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure
A Phase 2 study, sponsored by Advanz Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 400
- Enrollment target
NCT00063687: Completed Phase 2 study, sponsored by Advanz Pharma.
NCT00063687 is a Phase 2 study that has completed, run by Advanz Pharma. The registered enrollment target is 400 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (201% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00063687, a Phase 2 study, has completed, sponsored by Advanz Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 400 participants
- Enrollment target
Study Summary
The OPT-CHF (OxyPurinol Therapy for CHF) study is designed to demonstrate the efficacy and safety of oral oxypurinol vs. placebo in a randomized, double-blind, twenty-four week trial in 400 patients in up to 50 centers. Measures of clinical efficacy (NYHA class and Patient Global Assessment) as well as clinical outcomes (e.g., death, worsening heart failure, and hospitalization) will be assessed as a composite endpoint in this trial.
Interventions
- DRUG Oxypurinol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2003-03 |
| Est. Completion | 2005-06 |
| Phase | Phase 2 |
What the finished NCT00063687 record still lists
NCT00063687 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (201% higher).
The record links to 0 conditions, and to 1 intervention - of which Oxypurinol is the first listed.
NCT00063687 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00063687 about?
NCT00063687 is a clinical study titled "Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure". The OPT-CHF (OxyPurinol Therapy for CHF) study is designed to demonstrate the efficacy and safety of oral oxypurinol vs. placebo in a randomized, double-blind, twenty-four week trial in 400 patients in up to 50 centers. Measures of clinical efficacy (NYHA class and Patient Global Assessment) as well...
What is the current status of trial NCT00063687?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2003-03. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00063687?
The interventions under investigation include: Oxypurinol (DRUG).
Who is sponsoring clinical trial NCT00063687?
This trial is sponsored by Advanz Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00063687's enrollment target sits among peer trials
400 96th of 2000 higher than 1,898 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia